Peregrine Pharma Reports Q2 EPS $(0.07) Vs Est $(0.09), Sales $9.523M Vs Est $7.50M; Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New Clinical Trials Are Being Initiated--